Algorithm Picks Relevant Variables Variables help predict survivability with myelodysplastic syndromes

Aziz Nazha, MD from the Cleveland Clinic discusses algorithm picks relevant variables and variables help predict survivability with myelodysplastic syndromes at the 2017 American Society of Hematology... Author: ASHReport Added: 01/11/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

Publication date: Available online 23 May 2018 Source:Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology Author(s): Tomoya Soma, Seiji Asoda, Ryotaro Iwasaki, Hidetaka Miyashita, Mariko Inoue, Yuka Yamada, Kimio Uchiyama, Taneaki Nakagawa, Hiromasa Kawana Myelodysplastic syndrome is an acquired hematopoietic disorder showing symptoms of pre-leukemia and refractory anemia. In the tooth extraction process of such cases, bleeding tendency due to pancytopenia, infection etc., becomes a problem. As such, a cautious approach is required. We have confirmed platelet transfusion refractoriness prior to tooth extrac...
Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology - Category: ENT & OMF Source Type: research
We report outcomes of MDS patients with SF3B1 mutation in presence or absence of RS and their response to current available therapies.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Source: Blood - Category: Hematology Authors: Tags: Myeloid Neoplasia Letter to Blood Source Type: research
Myelodysplastic syndromes current treatment algorithm 2018, Published online: 24 May 2018; doi:10.1038/s41408-018-0085-4Myelodysplastic syndromes current treatment algorithm 2018
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
ker Higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) of the elderly exhibit several commonalities, including first line treatment with hypomethylating agents (HMA) like azacitidine (AZA) or decitabine (DAC). Until today, response to treatment occurs in less than 50 percent of patients, and is often short-lived. Moreover, patients failing HMA have a dismal prognosis. Current developments include combinations of HMA with novel drugs targeting epigenetic or immunomodulatory pathways. Other efforts focus on the prevention of resistance to HMA using checkpoint inhibitors to enhance immune attack. ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Authors: Vrbensky JR, Nazy I, Toltl LJ, Ross C, Ivetic N, Smith JW, Kelton JG, Arnold DM Abstract The mechanisms of platelet underproduction in immune thrombocytopenia (ITP) remain unknown. While the number of megakaryocytes is normal or increased in ITP bone marrow, further studies of megakaryocyte integrity are needed. Megakaryocytes are responsible for the production of platelets in the bone marrow, and they are possible targets of immune-mediated injury in ITP. Since the biological process of megakaryocyte apoptosis impacts platelet production, we investigated megakaryocyte DNA fragmentation as a marker of apop...
Source: Platelets - Category: Hematology Tags: Platelets Source Type: research
Authors: Senjo H, Higuchi T, Morimoto M, Koyamada R, Yanaoka C, Okada S Abstract An 81-year-old Japanese man presented with constitutional symptoms and anemia and was diagnosed with giant cell arteritis (GCA) and myelodysplastic syndrome (MDS) simultaneously. His symptoms and anemia improved promptly with steroids; however, the MDS rapidly progressed to overt leukemia. While MDS patients are at an increased risk of autoimmune diseases, an association with GCA has rarely been reported. This case illustrates the importance of considering GCA as a cause of anemia in elderly patients if MDS is already diagnosed, even i...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Yabe H PMID: 29780150 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Daitoku S, Aoyagi T, Takao S, Tada S, Kuroiwa M Abstract Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome that occurs as a complication in many clinical settings. Malignancy-associated HLH develops in patients with hematopoietic neoplasms, particularly in those with lymphoma, and its development in those with myelodysplastic syndrome (MDS) is uncommon. We herein report a case of HLH in a patient with low-risk MDS that was successfully treated with azacitidine. The prevalence of immune abnormalities among MDS patients and the immune effects of azacitidine have recently been elucidated...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
In the last few months two main streams of research have dominated the panorama of myelodysplastic syndrome investigations: one deepening the insight into pathogenic role, hierarchy and prognostic impact of somatic mutations and, as a consequence, into the impact of inherited congenital predisposing conditions; the second, quite interlinked in fact to the first one, analysing inflammation and innate immunity in myelodysplastic syndrome patients. The research devoted to clarifying mechanisms of action and mechanisms of resistance to hypomethylating agents has also advanced, mostly because of different approaches to the stud...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
More News: Cancer & Oncology | Hematology | Myelodysplastic Syndrome